Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $7.5 million.

  • Protagonist Therapeutics' Change in Accured Expenses rose 42.63% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 156.00%. This contributed to the annual value of $4.3 million for FY2024, which is 176.63% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Change in Accured Expenses is $7.5 million, which was up 119.40% from $3.4 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Change in Accured Expenses high stood at $13.0 million for Q3 2021, and its period low was -$11.8 million during Q1 2025.
  • Over the past 3 years, Protagonist Therapeutics' median Change in Accured Expenses value was $2.7 million (recorded in 2023), while the average stood at -$194,636.
  • As far as peak fluctuations go, Protagonist Therapeutics' Change in Accured Expenses spiked by 373.33% in 2021, and later slumped by 659.29% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Change in Accured Expenses (Quarterly) stood at $4.7 million in 2021, then tumbled by 197.53% to -$4.6 million in 2022, then fell by 16.35% to -$5.3 million in 2023, then surged by 160.47% to $3.2 million in 2024, then soared by 42.63% to $7.5 million in 2025.
  • Its Change in Accured Expenses was $7.5 million in Q3 2025, compared to $3.4 million in Q2 2025 and -$11.8 million in Q1 2025.